Lab Grifoni
Tertuliano Alves Pereira Neto
Yeji Lee
Nematullah Waseem
Leila Siddiqui
Alba Grifoni
T cells may offer some protection in an H5N1 ‘spillover’ scenario
New LJI research suggests many people already have T cells with the power to fight "highly pathogenic" avian influenza
San Diego scientists available to discuss mutated mpox strain
Scientists at La Jolla Institute for Immunology (LJI) lead new mpox vaccine research
LJI scientists lead new mpox research
San Diego scientists investigate how immune cells combat rapidly spreading mpox strain
Systemic and mucosal adaptive immunity to SARS-CoV-2 during the Omicron wave in patients with chronic lymphocytic leukemia
SARS-CoV-2 spike-specific regulatory T cells (Treg) expand and develop memory in vaccine recipients suggesting a role for immune regulation in preventing severe symptoms in COVID-19
Prior vaccination promotes early activation of memory T cells and enhances immune responses during SARS-CoV-2 breakthrough infection
Mpox vaccine and infection-driven human immune signatures: an immunological analysis of an observational study
Correlative CD4 and CD8 T-cell immunodominance in humans and mice: Implications for preclinical testing
Virus-specific stem cell memory CD8+ T cells may indicate a long-term protection against evolving SARS-CoV-2
Targets and cross-reactivity of human T cell recognition of common cold coronaviruses
An update on studies characterizing adaptive immune responses in SARS-CoV-2 infection and COVID-19 vaccination
Evidence for broad cross-reactivity of the SARS-CoV-2 NSP12-directed CD4+ T-cell response with pre-primed responses directed against common cold coronaviruses
Memory profiles distinguish cross-reactive and virus-specific T cell immunity to mpox
Humoral and cellular response induced by a second booster of an inactivated SARS-CoV-2 vaccine in adults
Prior cycles of anti-CD20 antibodies affect antibody responses after repeated SARS-CoV-2 mRNA vaccination
Corrigendum: Cross-reactive humoral and CD4+ T cell responses to Mu and Gamma SARS-CoV-2 variants in a Colombian population
Cross-reactive humoral and CD4+ T cell responses to Mu and Gamma SARS-CoV-2 variants in a Colombian population
Multi-omics analysis of mucosal and systemic immunity to SARS-CoV-2 after birth
Evaluation of cross-immunity to the Mpox virus due to historic Smallpox vaccination
Stimulation of Potent Humoral and Cellular Immunity via Synthetic Dual-Antigen MVA-Based COVID-19 Vaccine COH04S1 in Cancer Patients Post Hematopoietic Cell Transplantation and Cellular Therapy
Pre-existing SARS-2-specific T cells are predicted to cross-recognize BA.2.86
How COVID-19 ‘breakthrough’ infections alter your immune cells
LA JOLLA, CA—New research from scientists at La Jolla Institute for Immunology (LJI) suggests people who received COVID-19 vaccines and then experienced “breakthrough” infections are especially well armed against future SARS-CoV-2 infections.
T cells tackle new ‘Pirola’ SARS-CoV-2 variant
LJI scientists harness bioinformatics to predict how T cells may adapt to fighting the highly mutated Pirola variant
Alba Grifoni prepares to fight viral pandemics
LJI Research Assistant Professor Alba Grifoni, Ph.D., shares how her T cell research could propel vaccine development
Family resemblance: How T cells could fight many coronaviruses at once
LJI researchers work to head off future pandemics by uncovering key similarities between SARS-CoV-2 and common cold coronaviruses
¡Felicidades, Alba y Alex!
LJI COVID-19 researchers Alba Grifoni and Alessandro Sette win top honors from the Spanish Society of Immunology
Alba Grifoni receives ISSNAF award for COVID-19 research
New award from the Embassy of Italy honors an Italian scientist making breakthroughs in a global crisis
Exposure to common cold coronaviruses can teach the immune system to recognize SARS-CoV-2
Researchers caution: It is too soon to say whether pre-existing immune cell memory affects COVID-19 clinical outcomes
First detailed analysis of immune response to SARS-CoV-2 bodes well for COVID-19 vaccine development
Study finds robust antiviral T cell response in humans with COVID-19 and detects substantial crossreactivity in unexposed individuals; in a piece of good news provides a benchmark for testing of vaccine candidates.
LJI scientists identify potential targets for immune responses to novel coronavirus
Their analysis provides essential information for vaccine design and the evaluation of diagnostics and vaccine candidates
